COX-2 involvement in breast cancer metastasis to bone

Oncogene

Volumn 26, Issue 26, 2007, Pages 3789-3796

  Singh, B ^a   Berry, J A ^a   Shoher, A ^b,c   Ayers, G D ^a,d   Wei, C ^a   Lucci, A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

Bone metastasis; Breast cancer; Cancer prevention; COX 2; MF tricyclic; Mouse model

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MF TRICYCLIC; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE ATROPHY; BONE METASTASIS; BREAST ADENOCARCINOMA; CANCER CELL; CANCER MODEL; CELL ISOLATION; CELL POPULATION; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN FUNCTION; TREATMENT OUTCOME;

ANIMALS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; TRANSFECTION;

MUS;

EID: 34047217348     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210154     Document Type: Article

References (37)

1. Arguello F, Baggs RB, Frantz CN. (1988). A murine model of experimental metastasis to bone and bone marrow. Cancer Res 48: 6876-6881.
2. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P. (2004). COX-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2: 632-642.
3. Basu GD, Tinder TL, Bradley JM, Tu T, Hattrup CL, Pockaj BA et al. (2006). Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 177: 2391-2402.
4. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. (2003). Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33: 28-37.
5. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC et al. (2004). Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101: 591-596.
6. Connolly EM, Harmey JH, O'Grady T, Foley D, Roche-Nagle G, Kay E et al. (2002). Cyclooxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br J Cancer 87: 231-237.
7. Crawford YG, Gauthier ML, Joubel A, Mantei K, Kozakiewicz K, Afshari CA et al. (2004). Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. Cancer Cell 5: 263-573.
8. Fujita D, Yamashita N, Iita S, Amano H, Yamada S, Sakamoto K. (2003). Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. Prostaglandins Leukot Essent Fatty Acids 68: 351-358.
9. Gilhooly EM, Rose DP. (1999). The association between a mutated ras gene and cyclooxygenase-2 gene expression in human breast cancer cell lines. Int J Oncol 15: 267-270.
10. Girasole G, Passeri G, Jilka RL, Manolagas SC. (1994). Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest 93: 1516-1524.
11. Guo Q, Wang LH, Ruan KH, Kulmacz RJ. (1996). Role of Val509 in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents. J Biol Chem 271: 19134-19139.
12. Harms JF, Welch DR. (2003). MDA-MB-435 human breast carcinoma metastasis to bone. Clin Exp Metastasis 20: 327-334.
13. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. (2000). Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60: 2101-2103.
14. Hiraga T, Myoui A, Choi ME, Yoshikawa H, Yoneda T. (2006). Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res 66: 2067-2073.
15. Howe LR, Chang SH, Tolle KC, Dillon R, Young LJ, Cardiff RD et al. (2005). HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 65: 10113-10119.
16. Howe LR, Dannenberg AJ. (2003). COX-2 inhibitors for the prevention of breast cancer. J Mammary Gland Biol Neoplasia 8: 31-43.
17. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C et al. (2002). Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 62: 5405-5407.
18. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C et al. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549.
19. Khuder SA, Mutgi AB. (2001). Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84: 1188-1192.
20. Kundu N, Walser TC, Ma X, Fulton AM. (2005). Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother 54: 981-987.
21. Kundu N, Yang Q, Dorsey R, Fulton AM. (2001). Increased cyclooxygenase-2 expression and activity in a murine model of metastatic breast cancer. Int J Cancer 93: 681-686.
22. Lal G, Ash C, Hay K, Redston M, Kwong E, Hancock B et al. (2001). Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res 61: 6131-6136.
23. Li X, Pilbeam CC, Pan L, Breyer RM, Raisz LG. (2002). Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. Bone 30: 567-573.
24. Liu CH, Chang S-H, Narko K, Trifan OC, Wu M-T, Smith E et al. (2001). Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276: 18563-18569.
25. Morgan H, Tumber A, Hill PA. (2004). Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte/macrophage colony-stimulating factor. Int J Cancer 109: 653-660.
26. Ono K, Akatsu T, Murakami T, Kitamura R, Yamamoto M, Shinomiya N et al. (2002). Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res 17: 774-781.
27. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C et al. (2002). Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635.
28. Roche-Nagle G, Connolly EM, Eng M, Bouchier-Hayes DJ, Harmey JH. (2004). Antimetastatic activity of a cyclooxygenase-2 inhibitor. Br J Cancer 91: 359-365.
29. Shaheen NJ, Straus WL, Sandler RS. (2002). Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. Cancer 94: 950-963.
30. Singh B, Lucci A. (2002). Role of cyclooxygenase-2 in breast cancer. J Surg Res 108: 173-179.
31. Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A. (2005). COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 26: 1393-1399.
32. Singh B, Berry JA, Shoher A, Lucci A. (2006a). COX-2 induces IL-11 production in human breast cancer cells. J Surg Res 131: 267-275.
33. Singh B, Berry JA, Vincent LE, Lucci A. (2006b). Involvement of IL-8 in COX-2 mediated bone metastases from breast cancer. J Surg Res 134: 44-51.
34. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J. (2000). COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89: 2637-2645.
35. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. (2002). Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277: 18649-18657.
36. Wang D, DuBois RN. (2004). Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 31: 64-73.
37. Zhang S, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K. (2004). Vitamin E analog alpha-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice. Breast Cancer Res Treat 87: 111-121.